Death risk prediction after PCI in patients with coronary heart disease and heart failure based on random forest

HAN Gangfei; TIAN Jing; HE Zixuan; ZHANG Yajing; WU Tingyu; ZHANG Yanbo; HAN Qinghua

doi:10.16462/j.cnki.zhjbkz.2023.04.009

Volume 27 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2023 > 27(4): 425-430

HAN Gangfei, TIAN Jing, HE Zixuan, ZHANG Yajing, WU Tingyu, ZHANG Yanbo, HAN Qinghua. Death risk prediction after PCI in patients with coronary heart disease and heart failure based on random forest[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(4): 425-430. doi: 10.16462/j.cnki.zhjbkz.2023.04.009

Citation:

HAN Gangfei, TIAN Jing, HE Zixuan, ZHANG Yajing, WU Tingyu, ZHANG Yanbo, HAN Qinghua. Death risk prediction after PCI in patients with coronary heart disease and heart failure based on random forest[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(4): 425-430. doi: 10.16462/j.cnki.zhjbkz.2023.04.009

Citation:

HAN Gangfei, TIAN Jing, HE Zixuan, ZHANG Yajing, WU Tingyu, ZHANG Yanbo, HAN Qinghua. Death risk prediction after PCI in patients with coronary heart disease and heart failure based on random forest[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(4): 425-430. doi: 10.16462/j.cnki.zhjbkz.2023.04.009

PDF( 1304 KB)

Death risk prediction after PCI in patients with coronary heart disease and heart failure based on random forest

doi: 10.16462/j.cnki.zhjbkz.2023.04.009

1.
Department of Cardiology, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
2.
Department of Biostatistics, School of Public Health, Shanxi Medical University, Shanxi Provincial Key Laboratory of Major Assessment Diseases Risk, Taiyuan 030001, China

Funds:

National Natural Science Foundation of China 81970204

National Natural Science Foundation of China 82103958

Shanxi Provincial Key Research and Development Program 201903D421024

More Information

Corresponding author: ZHANG Yanbo, E-mail: sxmuzyb@126.com; HAN Qinghua, E-mail: syhqh@sohu.com
Received Date: 2022-01-05
Rev Recd Date: 2022-04-22

Available Online: 2023-04-28

Publish Date: 2023-04-10

Abstract

Abstract

Objective The study's objective is to use a random forest algorithm to analyze the influencing factors of death within a year after percutaneous coronary intervention (PCI) in patients with coronary atherosclerotic heart disease (coronary heart disease, CHD) and heart failure (HF). Methods A total of 1 078 inpatients who accepted PCI were enrolled from the First Hospital of Shanxi Medical University and Shanxi Cardiovascular Hospital from January 2014 to July 2019. All participants were followed up for 1 year, and death was chosen as the endpoint. A random forest algorithm was used to establish a prognostic model to analyze the influencing factors of death in the first year after PCI. Results The random forest model showed that red blood cell distribution width (RDW), heart rate, GLU, plasma albumin, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were the top five influencing factors of death. Conclusions RDW, heart rate, GLU, plasma albumin, and NT-proBNP were the top five influencing factors of death within a year after PCI in patients with CHD and HF. Our results provided a theoretical basis for the clinical evaluation of the benefits and risks for patients and the selection of treatment plans for doctors.
- Coronary heart disease,
- Heart failure,
- PCI,
- Prognosis,
- Random forest model

FullText(HTML)

References(18)

References

[1]	McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC [J]. Rev Esp Cardiol (Engl Ed), 2022, 75(6): 523. DOI: 10.1016/j.rec.2022.05.005.
[2]	Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure [J]. Nat Rev Cardiol, 2016, 13(6): 368-378. DOI: 10.1038/nrcardio.2016.25.
[3]	王昆, 石宇杰, 张健. 心力衰竭型冠心病患者经皮冠状动脉介入治疗效果预测因素分析[J]. 中国循证心血管医学杂志, 2015, 7(3): 374-377. DOI: 10.3969/j.1674-4055.2015.03.028. Wang K, Shi YJ, Zhang J. Predictive factors of curative effect of percutaneous coronary intervention in patients with heart failure of coronary heart disease [J]. Chin J Evid Based Cardiovasc Med, 2015, 7(3): 374-377. DOI: 10.3969/j.1674-4055.2015.03.028.
[4]	Alfonso F, Gonzalo N, Rivero F, et al. The year in cardiovascular medicine 2020: interventional cardiology [J]. Eur Heart J, 2021, 42(10): 985-1003. DOI: 10.1093/eurheartj/ehaa1096.
[5]	田晶, 杨弘, 陈鑫龙, 等. 冠心病合并心力衰竭患者死亡风险Cox回归模型分析[J]. 中国循证心血管医学杂志, 2020, 12(6): 683-686. DOI: 10.3969/j.issn.1674-4055.2020.06.10. Tian J, Yang H, Chen XL, et al. Analysis of Cox regression model of death risk in patients with coronary heart disease and heart failure [J]. Chin J Evid Based Cardiovasc Med, 2020, 12(6): 683-686. DOI: 10.3969/j.issn.1674-4055.2020.06.10.
[6]	Poludasu S, Marmur JD, Weedon J, et al. Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary intervention [J]. Thromb Haemost, 2009, 102(3): 581-587. DOI: 10.1160/TH09-02-0127.
[7]	Bujak K, Wasilewski J, Osadnik T, et al. The Prognostic Role of Red Blood Cell Distribution Width in Coronary Artery Disease: A Review of the Pathophysiology [J]. Dis Markers, 2015, 2015: 824624. DOI: 10.1155/2015/824624.
[8]	Wang RT, Takahashi K, Chichareon P, et al. The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial [J]. Atherosclerosis, 2020, 303: 1-7. DOI: 10.1016/j.atherosclerosis.2020.04.010.
[9]	Fosbøl EL, Seibaek M, Brendorp B, et al. Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study [J]. Int J Cardiol, 2010, 140(3): 279-286. DOI: 10.1016/j.ijcard.2008.11.084.
[10]	Lang CC, Gupta S, Kalra P, et al. Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: clinical evidence and pathophysiological mechanisms [J]. Atherosclerosis, 2010, 212: 1-8. DOI: 10.1016/j.atherosclerosis.2010.01.029.
[11]	Whelton SP, Narla V, Blaha MJ, et al. Association between resting heart rate and inflammatory biomarkers (high-sensitivity C-reactive protein, interleukin-6, and fibrinogen) (from the Multi-Ethnic Study of Atherosclerosis) [J]. Am J Cardiol, 2014, 113(4): 644-649. DOI: 10.1016/j.amjcard.2013.11.009.
[12]	Van der Horst IC, Nijsten MW, Vogelzang M, et al. Persistent hyperglycemia is an independent predictor of outcome in acute myocardial infarction [J]. Cardiovasc Diabetol, 2007, 6: 2. DOI: 10.1186/1475-2840-6-2.
[13]	Madani M, Alizadeh K, Ghazaee SP, et al. Elective percutaneous coronary intervention: the relationship between preprocedural blood glucose levels and periprocedural myocardial injury [J]. Tex Heart Inst J, 2013, 40(4): 410-417.
[14]	Timmer JR, Hoekstra M, Nijsten MW, et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention [J]. Circulation, 2011, 124(6): 704-711. DOI: 10.1161/CIRCULATIONAHA.110.985911.
[15]	Wada H, Dohi T, Miyauchi K, et al. Impact of serum albumin levels on long-term outcomes in patients undergoing percutaneous coronary intervention [J]. Heart Vessels, 2017, 32(9): 1085-1092. DOI: 10.1007/s00380-017-0981-8.
[16]	Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention [J]. J Am Coll Cardiol, 2003, 42(8): 1406-1411. DOI: 10.1016/s0735-1097(03)01044-1.
[17]	Zeng RX, Li XL, Zhang MZ, et al. Preprocedural N-terminal pro-B-type natriuretic peptide as a useful marker for predicting periprocedural myocardial injury following percutaneous coronary intervention in diabetic patients without cardiac dysfunction [J]. Scand J Clin Lab Invest, 2015, 75(7): 568-577. DOI: 10.3109/00365513.2015.1060518.
[18]	Bonaca MP, Wiviott SD, Sabatine MS, et al. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial) [J]. Am J Cardiol, 2007, 99(3): 344-348. DOI: 10.1016/j.amjcard.2006.08.035.